Sun Yunjing, Miao Bo, Cao Yabing, Cui Jiangman, Da Yingxiao, Qi Liping, Zhou Song
Xingtai Third Hospital, Cardiology Ward 2, Xingtai, China.
Xingtai Third Hospital, Coronary Care Unit, Xingtai, China.
J Med Biochem. 2024 Sep 6;43(5):704-710. doi: 10.5937/jomb0-47321.
The aim of the study was to examine the significance of plasma Transforming Growth Factor-1/TGF-β1 (TGF-β1) level testing in patients with Type 2 Diabetes Mellitus (T2DM) and heart failure.
A sample of T2DM patients who were hospitalised for dyspnea was chosen between June 2021 and June 2023. Based on the convenience sample approach, 150 cases were screened for the study, and 50 healthy non-diabetic people without cardiac problems who completed physical examinations over the same period were included as a control group. All study participants had their serum NT-proBNP and plasma TGF-I levels checked, and the values between the two groups were compared. Then, the patients with T2DM with heart failure were grouped according to whether they were accompanied by heart failure or not and the grading of cardiac function, and then the serum NT-proBNP and plasma TGF-β1 levels were compared between the different groups of patients. The diagnostic value of plasma TGF-β1 in the occurrence of heart failure in patients with T2DM was analysed.
There were 54 patients without heart failure and 96 people with heart failure among the 150 T2DM patients. The cut-off point was 44.50 g/L. At this time, the sensitivity and specificity for diagnosing concomitant heart failure in T2DM were 79.63% and 52.51%, respectively. 96 individuals with T2DM and heart failure showed greater serum and plasma levels of NT-proBNP and TGF-β1 compared to the other two groups (P=0.05). ProBNP and plasma TGF-β1 levels had a positive and significant relationship (P=0.05).
Plasma TGF-β1 levels were much higher in T2DM patients than in the general population, and the increase in this index was more pronounced in patients who also had heart failure, a diagnostic indicator for T2DM and heart failure.
本研究旨在探讨血浆转化生长因子-1/TGF-β1（TGF-β1）水平检测在2型糖尿病（T2DM）合并心力衰竭患者中的意义。
选取2021年6月至2023年6月因呼吸困难住院的T2DM患者作为样本。基于便利抽样法，筛选出150例患者进行研究，并纳入同期完成体检的50名无心脏问题的健康非糖尿病患者作为对照组。所有研究参与者均检测血清NT-proBNP和血浆TGF-I水平，并比较两组之间的数值。然后，将合并心力衰竭的T2DM患者根据是否伴有心力衰竭及心功能分级进行分组，再比较不同组患者的血清NT-proBNP和血浆TGF-β1水平。分析血浆TGF-β1对T2DM患者心力衰竭发生的诊断价值。
150例T2DM患者中，无心力衰竭者54例，有心力衰竭者96例。截断点为44.50 g/L。此时，T2DM患者诊断合并心力衰竭的灵敏度和特异度分别为79.63%和52.51%。与其他两组相比，96例合并心力衰竭的T2DM患者血清和血浆中的NT-proBNP和TGF-β1水平更高（P=0.05）。ProBNP与血浆TGF-β1水平呈显著正相关（P=0.05）。
T2DM患者血浆TGF-β1水平远高于普通人群，该指标在合并心力衰竭的患者中升高更为明显，是T2DM和心力衰竭的诊断指标。
